Abstract
Much remains unclear about the benefits and harms of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Between 2012 and 2018, we conducted two Cochrane systematic reviews on methylphenidate for ADHD. This article explores the main findings in relation to evidence-based practice and our current understanding of ADHD.
Bidragets oversatte titel | 基于发病机制治疗遗传性神经发育障碍的未来之路 |
---|---|
Originalsprog | Engelsk |
Tidsskrift | Clinical Pharmacology and Therapeutics |
Vol/bind | 104 |
Udgave nummer | 4 |
Sider (fra-til) | 606-609 |
ISSN | 0009-9236 |
DOI | |
Status | Udgivet - 13 jul. 2018 |